1.Red Cell Distribution Width: A Novel Marker of Activity in Inflammatory Bowel Disease.
Atakan YESIL ; Ebubekir SENATES ; Ibrahim Vedat BAYOGLU ; Emrullah Duzgun ERDEM ; Refik DEMIRTUNC ; Ayse Oya KURDAS OVUNC
Gut and Liver 2011;5(4):460-467
BACKGROUND/AIMS: Studies concerning red cell distribution width (RDW) for use in the assessment of inflammatory bowel disease (IBD) activity are limited. We investigated whether RDW is a marker of active disease in patients with IBD. METHODS: In total, 61 patients with ulcerative colitis (UC) and 56 patients with Crohn's disease (CD) were enrolled in the study group, and 44 age- and-sex-matched healthy volunteers were included as the control group. A CD activity index >150 in patients with CD indicated active disease. Patients with moderate and severe disease based on the Truelove-Witts criteria were considered to have active UC. In addition to RDW, serum C-reactive protein levels, erythrocyte sedimentation rates, and platelet counts were measured. RESULTS: Twenty-nine (51.7%) patients with CD and 35 (57.4%) patients with UC had active disease. The RDW was significantly higher in patients with CD and UC than in controls (p<0.001 and p<0.001, respectively). A subgroup analysis indicated that for a RDW cut-off of 14%, the sensitivity for detecting active CD was 79%, and the specicity was 93% (area under curve [AUC], 0.935; p<0.001). RDW was the most sensitive and specific marker for active CD. However, it was not valid for UC, as the ESR at a cutoff of 15.5 mm/hr showed a sensitivity of 83% and a specicity of 76% (AUC, 0.817; p<0.001), whereas the RDW at a cutoff of 14% showed 17% sensitivity and 84% specicity for detecting active UC. CONCLUSIONS: RDW was elevated in IBD in comparison with healthy controls and increased markedly in active disease. RDW may be a sensitive and specific marker for determining active CD, whereas ESR is an important marker of active UC.
Blood Sedimentation
;
C-Reactive Protein
;
Colitis, Ulcerative
;
Crohn Disease
;
Erythrocyte Indices
;
Humans
;
Inflammatory Bowel Diseases
;
Platelet Count
2.Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease.
Yusuf YILMAZ ; Talat AYYILDIZ ; Hakan AKIN ; Yasar COLAK ; Oguzhan OZTURK ; Ebubekir SENATES ; Ilyas TUNCER ; Enver DOLAR
Gut and Liver 2014;8(3):313-317
BACKGROUND/AIMS: We sought to examine whether the presence of gallstone disease (GD) in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) is associated with liver fibrosis and histological nonalcoholic steatohepatitis (NASH) score. METHODS: We included 441 Turkish patients with biopsy-proven NAFLD. GD was diagnosed in the presence of sonographic evidence of gallstones, echogenic material within the gallbladder with constant shadowing and little or no visualization of the gallbladder or absence of gallbladder at ultrasonography, coupled with a history of cholecystectomy. RESULTS: Fifty-four patients (12.2%) had GD (GD+ subjects). Compared with the GD- subjects, GD+ patients were older, had a higher body mass index and were more likely to be female and have metabolic syndrome. However, GD+ patients did not have a higher risk of advanced fibrosis or definite NASH on histology. After adjustment for potential confounding variables, the prevalence of GD in NAFLD patients was not associated with significant fibrosis (> or =2) (odds ratio [OR], 1.06; 95% confidence interval [CI], 0.53 to 2.21; p=0.68) or definite NASH (OR, 1.03; 95% CI, 0.495 to 2.12; p=0.84). CONCLUSIONS: The presence of GD is not independently associated with advanced fibrosis and definite NASH in adult Turkish patients with biopsy-proven NAFLD.
Biopsy
;
Fatty Liver/pathology
;
Female
;
Gallbladder/pathology
;
Gallstones/complications/*pathology
;
Humans
;
Liver/*pathology
;
Liver Cirrhosis/pathology
;
Male
;
Middle Aged
;
Non-alcoholic Fatty Liver Disease/complications/*pathology
;
Prospective Studies
;
Retrospective Studies
;
Sensitivity and Specificity
3.Impaired Gallbladder Motility and Increased Gallbladder Wall Thickness in Patients with Nonalcoholic Fatty Liver Disease.
Yasar COLAK ; Gulcin BOZBEY ; Tolga ERIM ; Ozge Telci CAKLILI ; Celal ULASOGLU ; Ebubekir SENATES ; Hasan Huseyin MUTLU ; Banu MESCI ; Mehmet Sait DOĞAN ; Guralp TASAN ; Feruze Yilmaz ENC ; Ilyas TUNCER
Journal of Neurogastroenterology and Motility 2016;22(3):470-476
BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide. Along with the increase in the incidence of NAFLD and associated obesity, an increase in gallbladder disease (GD) has been noted. This has led to the identification of a new disease entity called fatty GD. There is a gap in the literature on the dynamics of gallbladder function in patients with NAFLD. METHODS: An observational case-control study, a total of 50 patients with biopsy proven NAFLD without gallbladder stone/sludge and 38 healthy comparison subjects were enrolled. Fasting, postprandial gallbladder volumes (PGV), gallbladder ejection fraction (GEF), and fasting gallbladder wall thickness (FGWT) were measured by real-time 2-dimensional ultrasonography. RESULTS: Fasting gallbladder wall thickness, fasting gallbladder volumes and PGV were significantly higher in patients with NAFLD than control subjects (P < 0.001, P = 0.006, and P < 0.001, respectively). Gallbladder ejection fraction was significantly lower in the NAFLD group than the controls (P = 0.008). The presence of NAFLD was an independent predictor for GEF, PGV, and FGWT. Also, steatosis grade was an independent predictor for GEF, and GEF was significantly lower in the nonalcoholic steatohepatitis (NASH) subgroup than the controls. CONCLUSIONS: Gallbladder dysfunction and increase in gallbladder wall thickness exists in asymptomatic (without stone/sludge and related symptoms) patients with NAFLD and are useful in identifying fatty GD. Measurement of these variables in NAFLD patients may be useful in identifying those at higher risk for GD.
Biopsy
;
Case-Control Studies
;
Fasting
;
Gallbladder Diseases
;
Gallbladder*
;
Humans
;
Incidence
;
Liver Diseases
;
Non-alcoholic Fatty Liver Disease*
;
Obesity
;
Ultrasonography